Immuron Ltd — Regulatory Filings 2006

Mar 26, 2006

March 27th, 2006

Company Announcement Office Australian Stock Exchange Ltd (ASX) 4^th Floor, 20 Bridge Street Sydney NSW 2000

Dear Sir/Madam

Please find herewith a company announcement "Influenza Expert Appointed To Scientific Advisory Committee"" for release and distribution to the market immediately.

Yours sincerely

CONOR GRAHAM Managing Director & CEO

Influenza Program strengthened with new appointment to Scientific Advisory Committee

Anadis Limited (ASX:ANX) is pleased to announce the appointment of influenza expert, Associate Professor Lorena Brown, Associate Professor of Microbiology and Immunology at University of Melbourne, to the Scientific Advisory Committee. Professor Brown has been actively involved in influenza research both in Australia and the USA, which has led to over 90 published works including a book on options for the control of influenza. She has acted as an advisor to the World Health Organisation in Geneva on evaluation of immunity to influenza virus, and in 1996 was awarded the Ivanovsky Medal for her contribution to virology.

Associate Professor Brown will play a key role in the Anadis Influenza Research Program, with a desire to examine the use of polyclonal antibodies for prophylaxis and therapy. Dr Grant Rawlin, General Manager Research & Development, also has significant experience with avian influenza.

Anadis' influenza program will focus on a range of flu antigens (including H5 "bird flu"). looking for cross protection, between strains of the virus, by polyclonal antibodies, for which evidence already exists. Anadis ultimately plans to raise hyperimmune antibodies to provide passive immunity against influenza A viruses, which includes the current bird flu strain.

Oral and respiratory delivery of antibodies will be examined. Aspects of this technology come from the "Respiratory Protection" project performed in conjunction with the Department of Defence in the areas of respiratory delivery of antibodies and antibody fragments.

About Anadis Limited:

Anadis Ltd, a Melbourne based biopharmaceutical company focused on Nutraceutical and Pharmaceutical research and development. Anadis specialises in the development of bovine antibody - colostrum derived products for therapeutic use in humans. Projects include:

Anadis' first commercialised product: Travelan is a natural product, which significantly decrease the risk of the medical condition known as Travellers Diarrhoea and the symptoms of gastrointestinal disorders. Travelan is a bovine colostrum preparation, prepared from cows hyper-immunized against the 13 most common strains of E, coli – the most common cause of Travellers Diarrhoea (Bali Belly, Delhi Belly, etc.).

Travelan has recently received a "Green Light' for sales in the US and a distributor in Canada has been appointed. Travelan is being considered for other markets including: Singapore, India, Korea, United Arab Emirates, Thailand. Malaysia. South Africa and the UK and EU.

Travelan has recently been potentially identified for additional gastrointestinal indications including Irritable Bowel Syndrome IBS and Inflammatory Bowel Disorder IBD.

For more information please visit www.travelan.com.au

EV-71 - a bioactive protein based preventative product against Enterovirus 71, a debilitating polio like disease, is one of the viruses that causes 'hand, foot and mouth' or 'slapped cheek' disease. A significant proportion of vounger children effected can develop nervous signs such as fits, paralysis and Enterovirus 71 has the potentially to be fatal.

A set of Bio-Warfare/Respiratory Protection technologies, a project in conjunction with the Australian Department of Defence and US Bio-Defence Organisations, initially focused on short-term immediate protection from airborne bacteria such as Anthrax and Plague, future civilian applications include Hay Fever and Asthma.

C. difficile -the major diagnosed cause of infectious diarrhoea developing in patients following hospital admission in the United States - responsible for up to 75,000 fatalities each year. Anadis expects to have efficacy data in 6 months, and be at clinical trial phase within 12 to 18 months. This therapy can potentially be on the market in around 2 years. Given Anadis can already market colostrum based products in the US

Bio-Shield 10 a range of "bio-shielding" technologies which protect delicate molecules, enzymes and proteins, initially targeted for use in the pro-biotic market.

Development into an Immune Stimulating Infant Formula is underway, initially destined for the Asian market.

Pyloran, which has been clinically proven to reduce levels of H.pylori bacteria in the stomach and reduce the symptoms of H.pylori associated gastritis - Anadis is also in early development of a H.pylori vaccine.

For further information, please contact: Dr Grant Rawlin - General Manager Research & Development Email: grant.r@anadis.com.au +61 3 9358 6388 Arie Nudel - Investor Relations Email: arie.n@anadis.com.au +61 3 9358 6388

Visit our websites: www.anadis.com.au and www.travelan.com.au Anadis - Delivering On The Promise Of Biotechnology